Moderna (MRNA)

Moderna (MRNA) Stock Price & Analysis


MRNA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$62.55 - $217.25
Previous Close$78.28
Average Volume (3M)4.08M
Market Cap
Enterprise Value$24.15B
Total Cash (Recent Filing)$7.57B
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)-8.4
Feb 22, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.34
Shares Outstanding381,283,996
10 Day Avg. Volume2,741,356
30 Day Avg. Volume4,079,376
Standard Deviation0.26
Financial Highlights & Ratios
Price to Book (P/B)2.27
Price to Sales (P/S)1.55
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.98
Enterprise Value/Gross Profit1.74
Enterprise Value/Ebitda-6.72
Price Target Upside46.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16



Ownership Overview

17.00% Mutual Funds
43.13% Other Institutional Investors
39.87% Public Companies and Individual Investors


What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $62.55 and its highest was $217.25 in the past 12 months.
    What is Moderna’s market cap?
    Currently, no data Available
    When is Moderna’s upcoming earnings report date?
    Moderna’s upcoming earnings report date is Feb 22, 2024 which is in 77 days.
      How were Moderna’s earnings last quarter?
      Moderna released its earnings results on Nov 02, 2023. The company reported -$9.53 earnings per share for the quarter, missing the consensus estimate of -$1.932 by -$7.598.
        Is Moderna overvalued?
        According to Wall Street analysts Moderna’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Moderna pay dividends?
          Moderna does not currently pay dividends.
          What is Moderna’s EPS estimate?
          Moderna’s EPS estimate is -$1.4.
            How many shares outstanding does Moderna have?
            Moderna has 381,284,000 shares outstanding.
              What happened to Moderna’s price movement after its last earnings report?
              Moderna reported an EPS of -$9.53 in its last earnings report, missing expectations of -$1.932. Following the earnings report the stock price went down -6.522%.
                Which hedge fund is a major shareholder of Moderna?
                Among the largest hedge funds holding Moderna’s share is Flagship Pioneering Inc.. It holds Moderna’s shares valued at 998M.


                  Company Description


                  Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.


                  Top 5 ETFs holding MRNA

                  Market Value
                  Smart Score
                  Global X S&P 500 Covered Call ETF
                  iShares ESG Screened S&P 500 ETF
                  Global X S&P 500 Covered Call & Growth ETF
                  Global X S&P 500 ESG Covered Call ETF
                  Global X S&P 500 Tail Risk ETF
                  Up to five ETFs with an Outperform Smart Score that hold MRNA. The ETFs are listed according to market value of MRNA within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  BioNTech SE
                  Merck & Company

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis